StockData
SkinHealth Systems Inc. logo

SkinHealth Systems Inc. (SKIN) stock

SKINNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30316% above fair value
$13.88−1.18 (-7.81%)

Close on Nov 17, 2026Market cap $1.81BP/E –Yield –

SkinHealth Systems r&d expenses

Research and development expenses are spending on new products and technology.

SkinHealth Systems's R&D Expenses for the twelve months ending Jun 30, 2026 was $5.89M, up 28.6% year over year. For fiscal 2025 it was $5.63M, down 10.6% from the year before. The highest annual figure on record is $10.10M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$5.63M-10.6%
FY2024Dec 31, 2024$6.30M-37.7%
FY2023Dec 31, 2023$10.10M+19.6%
FY2022Dec 31, 2022$8.44M+3.0%
FY2021Dec 31, 2021$8.20M+140.4%
FY2020Dec 31, 2020$3.41M-26.1%
FY2019Dec 31, 2019$4.61M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.41M+12.5%
Q1 FY2026Mar 31, 2026$1.10M+10.4%
Q4 FY2025Dec 31, 2025$1.68M+37.6%
Q3 FY2025Sep 30, 2025$1.70M+53.2%
Q2 FY2025Jun 30, 2025$1.25M+7.9%
Q1 FY2025Mar 31, 2025$998.00K-64.4%
Q4 FY2024Dec 31, 2024$1.22M-59.9%
Q3 FY2024Sep 30, 2024$1.11M-39.7%
Q2 FY2024Jun 30, 2024$1.16M-59.8%
Q1 FY2024Mar 31, 2024$2.81M+20.2%
Q4 FY2023Dec 31, 2023$3.05M+110.7%
Q3 FY2023Sep 30, 2023$1.84M-15.1%
Q2 FY2023Jun 30, 2023$2.88M+10.8%
Q1 FY2023Mar 31, 2023$2.34M+4.8%
Q4 FY2022Dec 31, 2022$1.45M-22.9%
Q3 FY2022Sep 30, 2022$2.17M+15.3%
Q2 FY2022Jun 30, 2022$2.60M-13.0%
Q1 FY2022Mar 31, 2022$2.23M+53.6%
Q4 FY2021Dec 31, 2021$1.88M+118.0%
Q3 FY2021Sep 30, 2021$1.88M+225.8%
Q2 FY2021Jun 30, 2021$2.99M+400.5%
Q1 FY2021Mar 31, 2021$1.45M–
Q4 FY2020Dec 31, 2020$860.00K–
Q3 FY2020Sep 30, 2020$577.00K–
Q2 FY2020Jun 30, 2020$597.00K–

More SkinHealth Systems figures

See a number that looks wrong?